Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Read the original post:
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Related Posts